查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1308691

到 2030 年数字治疗市场预测 - 按类型、服务类型、购买模式、销售渠道（B2C、B2B）、最终用户和地区进行的全球分析

Digital Therapeutics Market Forecasts to 2030 - Global Analysis By Type, Service Type, Purchase Mode, Sales Channel (Business-to-Consumer and Business-to-Business ), End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球数字治疗市场规模将达到 66.8 亿美元，预测期内復合年增长率为 20.9%，到 2030 年将达到 252.4 亿美元，预计将达到美元。

数字疗法 (DTx) 使用基于证据、经过临床评估的软件和设备直接向患者提供医疗干预措施，以治疗、管理和预防各种疾病和病症。 例如，数字疗法可以帮助患者自我管理症状，改善生活质量和其他临床终点。 通过智能手机、移动设备和类似方式提供治疗，这些数字方式可以帮助缩小医疗保健方面的差距。

根据国际糖尿病联合会的数据，到 2021 年，全球 20-79 岁的糖尿病患者人数将从 2017 年的 4.25 亿增加到 5.37 亿。 预计到 2030 年，这一数字将达到 6.43 亿。

市场动态：

驱动程序

可预防的慢性疾病的患病率增加

慢性病的高患病率和发病率是世界各地医疗保健系统的主要关注点。 慢性病患者的治疗是一项重大挑战，因为心身和心理生理因素经常影响这些患者。 慢性病通常具有高度的不确定性，要求患者改变自己的行为，作为新的自我保健生活方式的一部分。 此外，许多慢性疾病和病症是进行性的，其患病率随着年龄的增长而增加。 因此，随着世界人口老龄化的显着增加，慢性病的数量预计将进一步增加。

限制

患者数据隐私问题

在许多国家，各种健康应用程序没有得到适当的批准，导致人们对产品和数据质量、对治疗决策的信任、患者隐私、安全性和负责任地使用数据的担忧。 数字治疗提供者可以访问患者信息，但禁止与不参与该患者护理的任何人共享该信息。 然而，使用数字工具进行数据整合会使患者数据面临被与患者护理计划无关的医疗保健专业人员访问的风险。

机会

製造商的战略举措

战略举措的实施可以为公司最重要的增长和扩张项目提供支持。 公司通常具备有效管理日常运营的能力，但新的战略举措往往是涉及多个工作流程的复杂项目。 我们的团队巧妙地支持与绿地和合併后整合相关的独特而復杂的任务流程，帮助客户照常专注于业务。

威胁

患者不愿接受数字化治疗

提高数字治疗的采用率和建立信任是数字治疗提供商面临的主要威胁。 老年人和服务不足的人群最容易感染疾病，患病率也最高，但由于技术素养水平较低，他们最不可能使用数字治疗产品。 此外，数字治疗可以观察到多少行为改变的限制仍有待确定。

COVID-19 的影响：

由于人们对数字健康价值的认识不断增强、精神疾病患病率上升以及药物滥用率上升，预计 COVID-19 大流行将对全球数字治疗市场产生积极影响。 此外，由于大流行迫使人们呆在家里，我们看到体力活动减少、生活方式选择增多、压力水平升高，所有这些都导致了慢性病的流行。 因此，DTx 硬件和软件在全球范围内的需求量很大。 此外，由于最近放宽了对基于 DTX 的疗法的监管审批，市场正在扩大。

疾病管理和治疗 DTx 细分市场将在预测期内成为最大的细分市场：

疾病管理和治疗 DTx 领域预计将在预测期内占据最大的市场份额。 在此背景下，慢性病患病率不断上升，疾病管理数字化治疗解决方案的价格可承受，数字化治疗的投资不断增加，医疗成本的经济负担日益沉重，同时还需要降低成本。

企业对企业 (B2B) 细分市场预计在预测期内復合年增长率最高：

企业对企业 (B2B) 细分市场正以市场上最高的复合年增长率增长。 这是由于提供者、付款人和雇主对数字疗法的好处越来越警惕，以及製药公司将数字疗法与其药品相结合的趋势。

份额最大的地区：

预计北美将在整个预测期内主导市场。 患有慢性疾病和药物滥用障碍等精神疾病的患者数量不断增加，是该区域市场占据主导地位的原因。 此外，由于主要公司之间有更多的合作伙伴关係和协议来专注于这些产品的研发，预计该地区也将增加这些设备的采用。

复合年增长率最高的地区：

由于越来越多地采用先进技术产品和有利的政府政策，预计亚太地区的复合年增长率最高。 医疗保健 IT 系统的需求量很大，因为它们可以有效地管理医院的临床、财务和行政方面。 此外，廉价的移动设备和互联网的广泛使用预计将增加对这些产品的需求，刺激区域市场的扩张。

主要进展：

2023年1月，Lupin Limited的全资子公司Lupin宣布推出其治疗解决方案LYFE。 LYFE 是印度唯一基于证据的整体心臟护理计划，可显着降低心脏病发作风险并改善心脏病患者的生命体征和生活质量。

2022 年 10 月，Fitbit Health Solutions 宣布与 Pretaa 建立合作伙伴关係。 通过将健康和活动数据纳入 Pretaa 的药物滥用康復应用程序，我们的目标是改善与药物滥用作斗争的美国人及其家人的治疗结果。

2022 年 8 月，Akili Inc.（一家针对多动症儿童的视频游戏类数字治疗设备製造商）宣布与特殊目的收购公司 Social Capital Suvretta Holdings Corp. 合併。

报告内容

  • 区域和国家级细分市场的市场份额评估
  • 给新进入者的战略建议
  • 2021 年、2022 年、2023 年、2026 年和 2030 年的综合市场数据
  • 市场趋势（驱动因素、限制因素、机遇、威胁、挑战、投资机会、建议）
  • 根据市场预测提出关键业务领域的战略建议
  • 竞争格局绘製主要共同趋势
  • 公司简介，包括详细的战略、财务状况和最新发展
  • 反映最新技术进步的供应链趋势

免费定制服务：

订阅此报告的客户将获得以下免费自定义选项之一：

  • 公司简介
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 主要公司的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家/地区的市场估计/预测/复合年增长率（注：基于可行性检查）
  • 竞争基准测试
    • 根据产品组合、地域分布和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第二章前言

  • 执行摘要
  • 利益相关者
  • 调查范围
  • 调查方法
    • 数据挖掘
    • 数据分析
    • 数据验证
    • 研究方法
  • 调查来源
    • 主要研究来源
    • 二手研究来源
    • 先决条件

第三章市场趋势分析

  • 驱动程序
  • 制约因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新冠肺炎 (COVID-19) 的影响

第 4 章波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间存在敌对关係

第 5 章全球数字治疗市场：按类型

  • 疾病管理/治疗 DTx
  • 疾病预防DTx

第 6 章全球数字治疗市场：按服务类型

  • 解决方案/软件
  • 设备
  • 服务
  • 硬件

第 7 章全球数字治疗市场：按购买类型

  • 个人购买
  • 集团采购组织

第 8 章全球数字治疗市场：按分销渠道划分

  • 企业对消费者 (B2C)
    • 病人
    • 看护者
  • B2B（B2B）
    • 付款人
    • 医疗保健提供者
    • 雇主
    • 製药公司
    • 其他企业对企业交易 (B2B)

第 9 章全球数字治疗市场：按最终用户划分

  • 预防
    • 糖尿病前期
    • 肥胖
    • 营养管理
    • 生活方式管理
    • 其他预防措施
  • 治疗/护理
    • 糖尿病
    • 中枢神经系统疾病
      • 心理健康障碍
      • 其他中枢神经系统疾病
    • 慢性呼吸系统疾病
    • 肌肉骨骼疾病
    • 心血管疾病
    • 禁止吸烟
    • 药物依从性
    • 消化系统疾病
    • 药物使用和成瘾管理
    • 康復与患者护理
    • 其他治疗/护理相关应用

第 10 章全球数字治疗市场：按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 意大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 新西兰
    • 韩国
    • 亚太地区其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 卡塔尔
    • 南非
    • 其他中东和非洲地区

第 11 章主要进展

  • 合同、合作伙伴关係、联盟和合资企业
  • 收购与合併
  • 推出新产品
  • 业务扩展
  • 其他关键策略

第12章公司简介

  • 2Morrow, Inc
  • Akili Interactive Labs, Inc.
  • BigHealth
  • Canary Health Inc.
  • DarioHealth Corp.
  • Dthera Sciences
  • Fitbit LLC
  • GAIA AG
  • HYGIEIA
  • Limbix Health, Inc.
  • Livongo Health, Inc.
  • Mango Health Inc.
  • Medtronic Plc.
  • Noom, Inc.
  • Omada Health, Inc.
  • Pear Therapeutics, Inc.
  • Propeller Health（ResMed）
  • Voluntis, Inc.
  • Welldoc, Inc.
Product Code: SMRC23391

According to Stratistics MRC, the Global Digital Therapeutics Market is accounted for $6.68 billion in 2023 and is expected to reach $25.24 billion by 2030 growing at a CAGR of 20.9% during the forecast period. In order to treat, manage, and prevent a wide range of diseases and disorders, digital therapeutics (DTx) delivers medical interventions directly to patients using evidence-based, clinically evaluated software and devices. Digital therapeutics, for instance, can assist patients in managing their symptoms on their own, enhancing their quality of life and other clinical endpoints. By offering therapeutics through smartphones, mobile devices, and comparable modalities, these digital modalities help to reduce the gaps in healthcare.

According to the International Diabetes Federation, globally, the number of people with diabetes aged 20-79 reached 537 million in 2021 from 425 million in 2017. This number is further estimated to reach 643 million by 2030.

Market Dynamics:

Driver:

Growing incidence of preventable chronic diseases

The high prevalence and incidence rate of chronic diseases is a major concern for healthcare systems across the globe. The treatment of patients with chronic diseases is a significant challenge, as psychosomatic or bio psychic factors very often influence these patients. As chronic diseases are often associated with high levels of uncertainty, patients need to change their behavior as part of a new self-care lifestyle. Furthermore, many chronic disorders and conditions are progressive, and their incidence increases with age. As a result, with significant growth in the global geriatric population, chronic disorders are expected to rise further in the coming years.

Restraint:

Patient data privacy concerns

In many countries, various health apps are deprived of appropriate approvals, leading to concerns of product & data quality, reliability in treatment decisions, patient privacy, security, and the responsible use of data. Digital therapeutics providers have access to patient information and are forbidden from sharing the information with anyone not involved in treating that patient. However, with the integration of data using digital tools, the patient's data is at risk of being accessed by any healthcare professional not related to the patient's treatment program.

Opportunity:

Strategic initiatives by manufacturers

Strategic initiatives practice supports companies undertaking the most important growth or expansion projects. While organizations are normally well-geared to manage the day-to-day aspects of business efficiently, major new strategic initiatives tend to be complex projects with multiple workstreams involved. The team helps clients maintain focus on business-as-usual functions by dexterously supporting the unique and complex task flows that accompany Greenfield integration or post-merger integration.

Threat:

Reluctance among patients to adopt digital therapeutics

Motivating people to use digital therapeutics and building their confidence is a major threat faced by digital therapeutics providers. While older and underserved populations show maximum susceptibility to diseases and the highest occurrence rates, they are the least likely to use digital therapeutics products due to low technology literacy levels. Furthermore, the limit of how much behavioural change will be observed with digital therapeutics is still undefined.

COVID-19 Impact:

The COVID-19 pandemic is anticipated to have a positive effect on the global market for digital therapeutics due to increased awareness of the value of digital health, an increase in the prevalence of mental illness, and a rise in the rate of drug abuse. Additionally, because people were forced to stay at home due to the pandemic, there was a decrease in physical activity, an increase in unhealthy lifestyle choices, and a rise in stress levels, all of which contributed to the prevalence of chronic diseases. As a result, DTx hardware and software are in greater demand all over the world. Additionally, the market is growing as a result of recent regulatory approvals for treatments based on DTX being more relaxed.

The disease management and treatment DTx segment is expected to be the largest during the forecast period:

Over the forecast period, it is anticipated that the disease management and treatment DTx segment will hold the largest market share. This is attributed to the rise in chronic disease prevalence, the availability of affordable digital therapeutic solutions for disease management, rising investments in digital therapeutics, and the need to reduce healthcare costs due to the rising economic burden of healthcare costs.

The business-to-business (B2B) segment is expected to have the highest CAGR during the forecast period:

The business-to-business (B2B) segment is growing at the highest CAGR in the market. This is attributed to increasing alertness among providers, payers, and employers about the benefits of digital therapeutics and the inclination of pharmaceutical companies to integrate digital therapeutics with their drug products.

Region with largest share:

Throughout the forecast period, North America is anticipated to rule the market. The increasing prevalence of patients with chronic illnesses and mental health conditions, such as substance use disorders, is responsible for the dominance of this regional market. Moreover, the introduction of these devices in the region is also anticipated to increase as a result of an increase in collaborations and agreements among the major players to concentrate on the research and development of these products.

Region with highest CAGR:

Due to the increased adoption of technologically advanced products and advantageous government policies, the Asia-Pacific market is estimated to witness the highest compound annual growth rate. The need for healthcare IT systems has been growing as they make it possible to manage hospitals' clinical, financial, and administrative aspects effectively. Additionally, it is anticipated that the widespread use of inexpensive mobile devices and the internet will increase demand for these products, spurring regional market expansion.

Key players in the market

Some of the key players profiled in the Digital Therapeutics Market include 2Morrow, Inc, Akili Interactive Labs, Inc., BigHealth , Canary Health Inc., DarioHealth Corp., Dthera Sciences, Fitbit LLC, GAIA AG, HYGIEIA, Limbix Health, Inc. , Livongo Health, Inc., Mango Health Inc., Medtronic Plc., Noom, Inc., Omada Health, Inc., Pear Therapeutics, Inc., Propeller Health (ResMed), Voluntis, Inc. and Welldoc, Inc.

Key Developments:

In January 2023, Lupin, a wholly-owned subsidiary of Lupin Limited, announced the launch of its therapeutics solution, LYFE. LYFE is India's only evidence-based holistic heart care programme that significantly reduces the risk of a heart attack and improves vitals and quality of life for cardiac patients.

In October 2022, Fitbit Health Solutions introduced a partnership with Pretaa that seeks to improve outcomes for Americans and their families affected by substance abuse by introducing health and activity data in Pretaa's substance abuse recovery app.

In August 2022, Akili Inc., the maker of a video game-like digital therapeutic for children with ADHD, announced the merger with a special-purpose acquisition company Social Capital Suvretta Holdings Corp.

Types Covered:

  • Disease Management and Treatment DTx
  • Disease Prevention DTx

Service Types Covered:

  • Solutions/Software
  • Device
  • Service
  • Hardware

Purchase Modes Covered:

  • Individual
  • Group Purchase Organization

Sales Channels Covered:

  • Business-to-Consumer (B2C)
  • Business-to-Business (B2B)

End Users Covered:

  • Preventive
  • Treatment/Care-related

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026 and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Digital Therapeutics Market, By Type

  • 5.1 Introduction
  • 5.2 Disease Management and Treatment DTx
  • 5.3 Disease Prevention DTx

6 Global Digital Therapeutics Market, By Service Type

  • 6.1 Introduction
  • 6.2 Solutions/Software
  • 6.3 Device
  • 6.4 Service
  • 6.5 Hardware

7 Global Digital Therapeutics Market, By Purchase Mode

  • 7.1 Introduction
  • 7.2 Individual
  • 7.3 Group Purchase Organization

8 Global Digital Therapeutics Market, By Sales Channel

  • 8.1 Introduction
  • 8.2 Business-to-Consumer (B2C)
    • 8.2.1 Patients
    • 8.2.2 Caregivers
  • 8.3 Business-to-Business (B2B)
    • 8.3.1 Payers
    • 8.3.2 Healthcare Provider
    • 8.3.3 Employers
    • 8.3.4 Pharmaceutical Companies
    • 8.3.5 Other Business-to-Business (B2B)

9 Global Digital Therapeutics Market, By End User

  • 9.1 Introduction
  • 9.2 Preventive
    • 9.2.1 Prediabetes
    • 9.2.2 Obesity
    • 9.2.3 Nutrition
    • 9.2.4 Lifestyle Management
    • 9.2.5 Other Preventive Applications
  • 9.3 Treatment/Care-related
    • 9.3.1 Diabetes
    • 9.3.2 CNS Disorders
      • 9.3.2.1 Mental Health Disorder
      • 9.3.2.2 Other CNS Disorders
    • 9.3.3 Chronic Respiratory Disorders
    • 9.3.4 Musculoskeletal Disorders
    • 9.3.5 Cardiovascular Diseases
    • 9.3.6 Smoking Cessation
    • 9.3.7 Medication Adherence
    • 9.3.8 Gastrointestinal Disorders
    • 9.3.9 Substance Use & Addiction Management
    • 9.3.10 Rehabilitation & Patient Care
    • 9.3.11 Other Treatment/Care-related Applications

10 Global Digital Therapeutics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 2Morrow, Inc
  • 12.2 Akili Interactive Labs, Inc.
  • 12.3 BigHealth
  • 12.4 Canary Health Inc.
  • 12.5 DarioHealth Corp.
  • 12.6 Dthera Sciences
  • 12.7 Fitbit LLC
  • 12.8 GAIA AG
  • 12.9 HYGIEIA
  • 12.10 Limbix Health, Inc.
  • 12.11 Livongo Health, Inc.
  • 12.12 Mango Health Inc.
  • 12.13 Medtronic Plc.
  • 12.14 Noom, Inc.
  • 12.15 Omada Health, Inc.
  • 12.16 Pear Therapeutics, Inc.
  • 12.17 Propeller Health (ResMed)
  • 12.18 Voluntis, Inc.
  • 12.19 Welldoc, Inc.

List of Tables

  • Table 1 Global Digital Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Digital Therapeutics Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Digital Therapeutics Market Outlook, By Disease Management and Treatment DTx (2021-2030) ($MN)
  • Table 4 Global Digital Therapeutics Market Outlook, By Disease Prevention DTx (2021-2030) ($MN)
  • Table 5 Global Digital Therapeutics Market Outlook, By Service Type (2021-2030) ($MN)
  • Table 6 Global Digital Therapeutics Market Outlook, By Solutions/Software (2021-2030) ($MN)
  • Table 7 Global Digital Therapeutics Market Outlook, By Device (2021-2030) ($MN)
  • Table 8 Global Digital Therapeutics Market Outlook, By Service (2021-2030) ($MN)
  • Table 9 Global Digital Therapeutics Market Outlook, By Hardware (2021-2030) ($MN)
  • Table 10 Global Digital Therapeutics Market Outlook, By Purchase Mode (2021-2030) ($MN)
  • Table 10 Global Digital Therapeutics Market Outlook, By Individual (2021-2030) ($MN)
  • Table 10 Global Digital Therapeutics Market Outlook, By Group Purchase Organization (2021-2030) ($MN)
  • Table 13 Global Digital Therapeutics Market Outlook, By Sales Channel (2021-2030) ($MN)
  • Table 14 Global Digital Therapeutics Market Outlook, By Business-to-Consumer (B2C) (2021-2030) ($MN)
  • Table 15 Global Digital Therapeutics Market Outlook, By Patients (2021-2030) ($MN)
  • Table 16 Global Digital Therapeutics Market Outlook, By Caregivers (2021-2030) ($MN)
  • Table 17 Global Digital Therapeutics Market Outlook, By Business-to-Business (B2B) (2021-2030) ($MN)
  • Table 18 Global Digital Therapeutics Market Outlook, By Payers (2021-2030) ($MN)
  • Table 19 Global Digital Therapeutics Market Outlook, By Healthcare Provider (2021-2030) ($MN)
  • Table 20 Global Digital Therapeutics Market Outlook, By Employers (2021-2030) ($MN)
  • Table 21 Global Digital Therapeutics Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 22 Global Digital Therapeutics Market Outlook, By Other Business-to-Business (B2B) (2021-2030) ($MN)
  • Table 23 Global Digital Therapeutics Market Outlook, By End User (2021-2030) ($MN)
  • Table 24 Global Digital Therapeutics Market Outlook, By Preventive (2021-2030) ($MN)
  • Table 25 Global Digital Therapeutics Market Outlook, By Prediabetes (2021-2030) ($MN)
  • Table 26 Global Digital Therapeutics Market Outlook, By Obesity (2021-2030) ($MN)
  • Table 27 Global Digital Therapeutics Market Outlook, By Nutrition (2021-2030) ($MN)
  • Table 28 Global Digital Therapeutics Market Outlook, By Lifestyle Management (2021-2030) ($MN)
  • Table 29 Global Digital Therapeutics Market Outlook, By Other Preventive Applications (2021-2030) ($MN)
  • Table 30 Global Digital Therapeutics Market Outlook, By Treatment/Care-related (2021-2030) ($MN)
  • Table 31 Global Digital Therapeutics Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 32 Global Digital Therapeutics Market Outlook, By CNS Disorders (2021-2030) ($MN)
  • Table 33 Global Digital Therapeutics Market Outlook, By Chronic Respiratory Disorders (2021-2030) ($MN)
  • Table 34 Global Digital Therapeutics Market Outlook, By Musculoskeletal Disorders (2021-2030) ($MN)
  • Table 35 Global Digital Therapeutics Market Outlook, By Cardiovascular Diseases (2021-2030) ($MN)
  • Table 36 Global Digital Therapeutics Market Outlook, By Smoking Cessation (2021-2030) ($MN)
  • Table 37 Global Digital Therapeutics Market Outlook, By Medication Adherence (2021-2030) ($MN)
  • Table 38 Global Digital Therapeutics Market Outlook, By Gastrointestinal Disorders (2021-2030) ($MN)
  • Table 39 Global Digital Therapeutics Market Outlook, By Substance Use & Addiction Management (2021-2030) ($MN)
  • Table 40 Global Digital Therapeutics Market Outlook, By Rehabilitation & Patient Care (2021-2030) ($MN)
  • Table 41 Global Digital Therapeutics Market Outlook, By Other Treatment/Care-related Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, Asia Pacific, South America and Middle East & Africa Regions are also represented in the same manner as above.